Barclays analyst Peter Lawson lowered the firm’s price target on MacroGenics to $9 from $14 and keeps an Overweight rating on the shares. “Out of an abundance of caution,” the analyst trimmed the probability of success in penetration in prostate cancer given competitive dynamics including from multiple PSMA therapies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGNX: